

Clinical Center (CC) Animal Care and Use Committee

Minutes of Meeting

10 CRC 3-2550

Date: 2/19/20

Members present:

Virginia Guptill, PhD, ORSC, Chair	Redacted by agreement
Redacted by agreement	
Lisa Portnoy, DVM, ACP	
Redacted by agreement	

Members absent:

Redacted by agreement	Redacted by agreement	

5 Members needed for quorum

Executive Secretary:

Redacted by agreement

\*\*\*\*\*

Guest Observer:

--	--

Presenters:

Redacted by agreement	

(b)(5)



Redacted by agreement

Proposal review

Redacted by agreement

- Non-Research Maintenance of Experimental Animals.

This proposal was approved with editorial changes.

Vote: Unanimous

Redacted by agreement

Annual review

Redacted by agreement

- General Protocol for Testing Radiopharmaceuticals in Mice and Rats.

The committee agreed to approve this with editorial changes.

- Correct the numbers listed on the top of page 2.

Vote: Unanimous

**Approval under Significant Change Policy:**

**Veterinary approval:**

Redacted by agreement

Procedure addition: Fasting

Redacted by agreement

Procedure addition: Microwave ablation

**Coordinator approval:**

Redacted by agreement

Personnel addition:

Redacted by agreement

Redacted by agreement

Personnel addition:

Redacted by agreement

Procedure space:

Redacted by agreement

Personnel addition:

Redacted by agreement

Redacted by agreement

ASPs) Procedure space addition

Redacted by agreement

**Stipulated Protocol status:**

Redacted by agreement

Proposal review - Probing Nanomechanics of Inner Ear Tissues. (Breeding protocol)

Status: **Approved**

Redacted by agreement

Proposal review - Murine Immune Responses to Biomaterials in the Presence and Absence of Trauma.

Status: **Approved**

Redacted by agreement

Amendment review

Redacted by agreement

PET and MRI Characterization of Infectious Disease Models.

Redacted by agreement

presented this amendment.

Status: **Approved**

(b)(5)

Status: Pending

Redacted by agreement

Proposal review, Effect of P12K/AKT Inhibition on Pulmonary Vascular Remodeling in the SU-5416/Hypoxia/Normoxia Rat Model of Pulmonary Arterial Hypertension.

Status: **Approved**

(b)(5)

Status: Pending

(b)(5)

Status: Pending

**Designated review status:**

N/A

**Inactivated Protocols:**

N/A

Other business:

N/A

Old Business:

N/A

**Next meeting:** March 18, 2020 9:00am

Virginia Guptill, PhD, ORSC

Clinical Center (CC) Animal Care and Use Committee

Minutes of Meeting

Webex teleconference due to social distancing.

Date: 3/18/20

Members present:

Virginia Guptill, PhD, ORSC, Chair	Redacted by agreement
Redacted by agreement	
Lisa Portnoy, DVM, ACP	
Redacted by agreement	

Members absent:

Redacted by agreement	

5 Members needed for quorum

Executive Secretary:

Redacted by agreement

\*\*\*\*\*

Guest Observer:

Redacted by agreement

Presenters:


(b)(5)

Redacted by agreement

Amendment review

Redacted by agreement

Investigation of the Effects of a programmed death-ligand 1 (PD-L1) Inhibitor and Semaphorin 5A in a Murine Model of Pneumonia.

This amendment was approved with editorial changes.

The following corrections were sent to the PI:

- Please confirm that no additional animals are being requested.

Vote: Unanimous

(b)(5)

Redacted by agreement

1. Amendment review Redacted by agreement - Determining the Role of Iron and Nitric Oxide in Cell Free Hemoglobin Induced Injury in a Canine Model of *S. aureus* Pneumonia. Does Haptoglobin Have a Therapeutic Role?

The committee agreed to approve this amendment with one clarification to the PI:

- (b)(5)

Vote: Unanimous

2. Proposal review Redacted by agreement - Non-Research Holding and Maintenance of Canines.

The committee agreed to approve with editorial changes.

The following corrections were sent to the PI:

- a. Please add page numbers, line numbers and the title in the header.
- b. Please include what circumstances would require contact. If there are none, please put N/A or "none".

Vote: Unanimous

(b)(5)

3. Annual review [Redacted by agreement] Intravital Microscopic Imaging of Nanoformulations.

The committee agreed to approve this amendment with editorial changes.

The following was sent to the PI:

- Please define NP

Vote: Unanimous

(b)(5)

[Redacted by agreement]

Annual review [Redacted by agreement] Animal Health Surveillance Using Sentinel Animals in the [Redacted by agreement] Shared Animal Facility.

The committee agreed to approve this annual review.

Vote: Unanimous

[Redacted by agreement]

1. Annual review [Redacted by agreement] Advanced MRI to Monitor Effects of Neuroprotective Agents for Traumatic Brain Injury (TBI) in Rodents.

The committee agreed to approve this annual review.

Vote: Unanimous

2. Annual review [Redacted by agreement] Development of Advanced MRI Techniques in Rodents.

The committee agreed to approve this annual review.

Vote: Unanimous

**Approval under Significant Change Policy:**

**Veterinary approval:**

N/A

**Coordinator approval:**

N/A

**Stipulated Protocol status:**

(b)(5)

Status: Pending

(b)(5)

Status: Pending

[Redacted by agreement]



Amendment review

Redacted by agreement

- Investigation into the Biology, Biochemistry, Immunology, and Therapy of

Pneumocystis Infection

Status: **Approved**

Redacted by agreement

CCM

Annual review

Redacted by agreement

- Determining the Role of Iron and Nitric Oxide in Cell Free Hemoglobin Induced Injury in a Canine Model of S. aureus Pneumonia. Does Haptoglobin Have a Therapeutic Role?

Status: **Approved**

(b)(5)

Status: Pending

Redacted by agreement

DRD

DRD Proposal review - Woodchuck Model of Hepatocellular Carcinoma: Development of the Model and Interventional Oncology Applications.

Status: **Approved**

DRD Proposal review - Radiologic Imaging and Interventional Therapies: Development and Assessment of New Technologies and Applications in Swine.

Status: **Approved**

Amendment review

Redacted by agreement

- Evaluating Immune Response to Minimally Invasive or Non-invasive Ablation in Mice.

Redacted by agreement

presented this amendment.

Status: **Approved**

Designated review status:

N/A

Inactivated Protocols:

N/A

Other business:

Post Approval Monitoring form was reviewed. There was an adjustment to the monitoring procedure to switch from selecting one protocol per month to meeting with one department per month with a focus on the most complex studies within that department.

Old Business:

N/A

**Next meeting:** April 15, 2020 9:00am

Virginia Guptill, PhD, ORSC

Clinical Center (CC) Animal Care and Use Committee

Minutes of Meeting

Teleconference due to social distancing (COVID-19).

Date: 4/15/20

Members present:

Virginia Guptill, PhD, ORSC, Chair	Redacted by agreement
Redacted by agreement	
Lisa Portnoy, DVM, ACP	
Redacted by agreement	

Members absent:

Redacted by agreement		Redacted by agreement	

5 Members needed for quorum

Executive Secretary:

Redacted by agreement
-----------------------

\*\*\*\*\*

Guest Observer:

Redacted by agreement		
-----------------------	--	--

Presenters:

Redacted by agreement		

(b)(5)





(b)(5)

**Approval under Significant Change Policy:**

**Veterinary approval:**

N/A

**Coordinator approval:**

N/A

**Stipulated Protocol status:**

Redacted by agreement

**Proposal review** Redacted by agreement - Evaluation of Analgesics, Genes, Neurotransmitters and Diseases in Nociception and Locomotion.

Status: **Approved**

Redacted by agreement

**Proposal review** Redacted by agreement - Maintenance of IQGAP1 -null Mouse Colony.

Redacted by agreement presented this amendment.

Status: **Approved**

Redacted by agreement

**Amendment review** Redacted by agreement - Probing Nanomechanics of Inner Ear Tissues.

Status: **Approved**

Redacted by agreement

**Amendment review** Redacted by agreement - Investigation of the Effects of a programmed death-ligand 1 (PD-L1) Inhibitor and Semaphorin 5A in a Murine Model of Pneumonia.

Status: **Approved**

(b)(5)

Status: Pending

3. Redacted by agreement **Amendment review** - Intravital Microscopic Imaging of Nanoformulations. (Kupffer cells)

Status: **Approved**

4. **Amendment review** Redacted by agreement - Biomedical Applications of Nanoformulations. (Dox)

Status: **Approved**

Redacted by agreement

**Amendment review** Redacted by agreement - PET and MRI Characterization of Infectious Disease Models.

Status: **Approved**

**Designated review status:**

Redacted by  
agreement

The Effects of Prior Checkpoint Inhibitor (CPI) Therapy on Mouse Hepatitis Coronavirus Induced Pneumonia.

Status: **Approved**

**Inactivated Protocols:**

Redacted by  
agreement

The Effects of TNF Soluble Receptor, a Selective TNF Inhibitor, on the Inflammatory Effects of *B. anthracis* Cell Wall Peptidoglycan in a Rat Model.

**Other business:**

1. Semiannual inspection – our inspection has been temporarily waived under the OACU campus waiver with OLAW. We will complete this inspection once the social distancing directive has been lifted. The semiannual report was distributed to the committee for review and signature.
2. Program review – the program description review has been performed by Dr. Portnoy and Redacted by agreement. There were no major changes needed to the program. The description format has been changed according to the format required by AAALAC.
3. Scientific Review Policy was reviewed by the committee, no changes were made.
4. Chemical Compound form was revised to include a justification section for the principal investigator to complete. If any compounds fall under category 4 as defined by the form (Categories: 1. Compounds are not commercially available as pharmaceutical grade, 2. Compounds are available pharmaceutical grade but not in a formulation suitable for this study(e.g., tablet form when injectable is required), 3. Non--pharmaceutical grade compounds have been used previously and are needed to directly compare new results with the same compounds, 4. Other--provide brief justification below.) The justification section will need to be completed. The form was also amended to include a link to the ARAC guideline for the use of Non-pharmaceutical grade compounds and an excerpt from the Guide was also added.

**Old Business:**

N/A

**Next meeting:** May 20, 2020 9:00am

Virginia Guptill, PhD, ORSC

Clinical Center (CC) Animal Care and Use Committee  
Minutes of Meeting  
Teleconference due to social distancing (COVID-19).  
Date: 5/20/20

**Members present:**

Virginia Guptill, PhD, ORSC, Chair	Redacted by agreement
Redacted by agreement	
Lisa Portnoy, DVM, ACP	
Redacted by agreement	

**Members absent:**

Redacted by agreement		

5 Members needed for quorum

**Executive Secretary:**

Redacted by agreement

\*\*\*\*\*

**Guest Observer:**

Redacted by agreement

**Presenters:**

Redacted by agreement		

Redacted by agreement

Amendment review Redacted by agreement PET and MRI characterization of infectious disease models.  
This amendment was approved with the distribution of the revised B3 SOPs.

Vote: Unanimous

(b)(5)

(b)(5)

**Approval under Significant Change Policy:**

**Veterinary approval:**

N/A

**Coordinator approval:**

N/A

**Stipulated Protocol status:**

Redacted by agreement

**Proposal review** Redacted by agreement Preclinical Trials of Novel Therapies for Sickle Cell Disease: Their Effect on Nociception, Disease Progression, Behavior, and Metabolic Markers in Mouse Models of Sickle Cell Disease (SCD).  
Status: **Approved**

(b)(5)

Status: Pending

(b)(5)

Status: Pending

(b)(5)

Status: Pending

**Designated review status:**

N/A

**Inactivated Protocols:**

N/A

**Other Business:**

1. OLAW findings report review. Committee discussed responses and agreed upon the proposed response. Dr. Portnoy is to provide a formal response to OACU by June 15<sup>th</sup>.
2. Update on other pending COVID projects.
  - (b)(5)
  -
3. Significant change VVC policy discussed continuation of the policy. The committee agreed we should continue with the policy. Dr. Portnoy to revise document and present at the next meeting.

**Old Business:**

N/A



**Next meeting:** June 17, 2020 9:00am

Virginia Guptill, PhD, ORSC

Clinical Center (CC) Animal Care and Use Committee  
 Minutes of Meeting  
 Teleconference due to social distancing (COVID-19).  
 Date: 6/17/2020

Members present:

Virginia Guptill, PhD, ORSC, Chair	Redacted by agreement
Redacted by agreement	
Lisa Portnoy, DVM, ACP	
Redacted by agreement	

Members absent:

Redacted by agreement		Redacted by agreement	

5 Members needed for quorum

Executive Secretary:

Redacted by agreement
-----------------------

\*\*\*\*\*

Guest Observer:

Redacted by agreement		
-----------------------	--	--

Presenters:

Redacted by agreement		

(b)(5)

Redacted by agreement
-----------------------

Redacted by  
agreement

annual review - Development and Use of an ex-vivo Rat Lung Perfusion Model to Investigate the Effects of Anthrax Edema and Lethal Toxin on Pulmonary Vascular Endothelial Function.

Disposition Vote: Approved

(b)(5)

(b)(5)

Redacted by agreement

Redacted by agreement

annual review – Development of Molecular Therapeutics for Diabetes.

Disposition vote: require modifications to secure approval.

The following modifications were sent to the PI:

- Emergency form: please add N/A for answers to questions on lines 33 and 34

Vote: Unanimous

**The Investigator responded with the necessary changes and the review was approved through DMR**

(b)(5)

**Approval under Significant Change Policy:**

**Veterinary approval:**

N/A

**Coordinator approval:**

N/A

**Stipulated Protocol status:**

Redacted by agreement

**Amendment review**

Redacted by agreement

Status: **Approved**

General Protocol for Testing Radiopharmaceuticals in Mice and Rats. (FAP)

Amendment review Redacted by agreement Protocol for Molecular Imaging of Cancer Therapy Response. (FAP)  
Status: **Approved**

(b)(5)

Status: Pending

(b)(5)

Status: Pending

(b)(5)

Status: pending

**Designated review status:**

N/A

**Inactivated Protocols:**

Redacted by agreement

Delineating Mechanisms Underlying B. anthracis Edema Toxin's Arterial Relaxant Effects Using the Isolated Aortic Ring Model.

**Other Business:**

Significant change policy: Dr. Portnoy reviewed the revised policy with the committee. No further changes were needed The policy will be added to our ACUC policies.

**Old Business:**

N/A

**Next meeting:** July 15, 2020 9:00am

Virginia Guptill, PhD, ORSC

Clinical Center (CC) Animal Care and Use Committee  
Minutes of Meeting  
Teleconference due to social distancing (COVID-19).  
Date: 7/15/2020

**Members present:**

Redacted by agreement		Redacted by agreement
Lisa Portnoy, DVM, ACP		
Redacted by agreement		

**Members absent:**

Redacted by agreement	Redacted by agreement
Virginia Guptill, PhD, ORSC, Chair	

5 Members needed for quorum

**Executive Secretary:**

Redacted by agreement
-----------------------

\*\*\*\*\*

**Guest Observer:**

--	--

**Presenters:**

Redacted by agreement		

(b)(5)



**Approval under Significant Change Policy:**

**Veterinary approval:**

N/A

**Coordinator approval:**

N/A

**Stipulated Protocol status:**

Redacted by agreement

**Amendment review** Redacted by agreement Radiologic Imaging and Interventional Therapies: Development and Assessment of New Technologies and Applications in Swine.

Status: **Approved**

Redacted by agreement

**Proposal review** - Characterizing ACE2 Downregulation Through Binding to SARS-CoV-2 Spike Protein in Mouse Models.

Status: **Approved**

Redacted by agreement

Redacted by agreement

**annual review** - SU-5416/Hypoxia/Normoxia Rat Model of Pulmonary Arterial Hypertension.

Status: **Approved**

Redacted by agreement

**Amendment review** Redacted by agreement

Intravital Microscopic Imaging of Nanoformulations. (Liver mets)

Status: **Approved**

**Amendment review** Redacted by agreement

Biomedical Applications of Nanoformulations. (CIA)

Status: **Approved**

Redacted by agreement

**annual review w/ amendment** - Protocol for Development of Therapeutic Radiopharmaceuticals.

Status: **Approved**

**Designated review status:**

N/A

**Inactivated Protocols:**

N/A

**Other Business:**

N/A

**Old Business:**

N/A

**Next meeting:** August 19, 2020 9:00am

Virginia Guptill, PhD, ORSC